Skip to content

Clinical trials

Phase 3 Amyloidosis trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Amyloidosis Phase: Phase 3 Country / region: United States Clear all

27 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20091
20102
20121
20132
20141
20151
20161
20171
20194
20202
20211
20221
20232
20242
20253
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Recruiting5
Active, not recruiting3
Enrolling by invitation2
Terminated2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Alnylam Pharmaceuticals7
Ionis Pharmaceuticals, Inc.4
Eidos Therapeutics, a BridgeBio company3
Pfizer3
Brigham and Women's Hospital2
Alexion Pharmaceuticals, Inc.1
C.T. Development America, Inc.1
Intellia Therapeutics1
Janssen Research & Development, LLC1
Millennium Pharmaceuticals, Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Amyloidosis27
Amyloid Neuropathies, Familial11
Cardiomyopathies9
Alzheimer Disease5
Amyloidosis, Familial4
Polyneuropathies4
Disease2
Heart Diseases2
Amyloid Neuropathies1
Immunoglobulin Light-chain Amyloidosis1

Trials

Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.